Eli Lilly and Co. plans to streamline operations that will result in global workforce reductions impacting approximately 3,500 positions. The company expects annual savings of approximately $500 million that will begin to be realized in 2018. Lilly expects the majority of the positions eliminated to come from a U.S. voluntary early retirement program. The program will be mostly complete by December 31, 2017.
Remaining positions will come from other anticipated workforce reductions, including select site closures. The company will move production from its animal health manufacturing facility in Larchwood, IA, to an existing plant in Fort Dodge, IA. In addition, an R&D office in Bridgewater, NJ, and the Lilly China R&D Center in Shanghai will close.
"We have an abundance of opportunities—eight medicines launched in the past four years and the potential for two more by the end of next year," said David A. Ricks, Lilly's chairman and chief executive officer. "To fully realize these opportunities and invest in the next generation of new medicines, we are taking action to streamline our organization and reduce our fixed costs around the world. The actions will result in a leaner, more nimble global organization and will accelerate progress towards our long-term goals of growing revenue, expanding operating margins and sustaining the flow of life-changing medicines from our pipeline."
Breaking News
Lilly Restructures
To cut global workforce by approximately 3,500
09.08.17
Related Breaking News
-
Breaking News | cGMP Manufacture | Industry News
Valneva Inks APA with European Commission for COVID Vax
To supply up to 60 million doses of its inactivated COVID-19 vaccine candidate, VLA2001, over two years.11.23.21
-
Breaking News | Industry News | R&D
AstraZeneca Unveils £1B R&D Facility in Cambridge UK
New facility, designed to the highest environmental standards, will include advanced robotics, high-throughput screening and AI-driven technology.11.23.21
-
Breaking News | cGMP Manufacture | Facilities
Concept Life Sciences Receives GMP Accreditation for UK Site
Strengthens its position as a trusted partner to pharmaceutical, biotech and animal health companies.11.23.21
-
Bioanalytical Services | Biologics, Proteins, Vaccines | Breaking News | Industry News | Laboratory Testing | Microbiology
Lonza Expands Microbial Development Labs
New development capacity will consolidate the microbial footprint at the Visp site and add new high throughput equipment and automation processes.11.23.21
-
Breaking News | Industry News | Vials
Bormioli Pharma Joins the Glass Futures Project
Aims to research and make available state-of-the-art technologies and processes to reduce the environmental impact of glass production.11.23.21
-
Breaking News | Fill/Finish | Industry News | Vials
Steriline Showcases New Robotic Nest Filling Machine
Features of the RayDyLyo closure system are designed to be more suitable to produce small and medium volumes in R&D labs or pilot lines.11.23.21
-
Breaking News | Facilities
Owen Mumford Begins Construction on New Production Facility in Oxfordshire, UK
The new building is commissioned to align with the company’s sustainability agenda.11.22.21
-
Breaking News | Drug Development
Regenxbio Receives FDA Orphan Drug Designation for Potential Duchenne Treatment
Marks a milestone in the development of RGX-202 and highlights the need for potential new treatment options for patients with Duchenne.11.22.21
-
Breaking News | Drug Development
Neurocrine Biosciences & Sosei Group Collaborate to Develop Treatment for Neuropsychiatric Disorders
Sosei Heptares receives $100 million upfront, ongoing R&D funding and up to $2.6 billion in potential development, regulatory and commercial milestone payments.11.22.21
-
Breaking News | Collaborations & Alliances | Drug Development | R&D
Evotec SE, EQRx Enter Oncology, Immunology R&D Alliance
Aims to accelerate EQRx's pipeline leveraging Evotec's data-driven, integrated R&D-platform, applied across different drug modalities and therapeutic areas.11.19.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Trials & Filings
BioNTech's FixVac Gets Fast Track in Advanced Melanoma
FixVac platform uses a fixed combination of mRNA-encoded, tumor-associated antigens to trigger a precise immune response against cancer.11.19.21
-
Breaking News | Industry News
Pfizer, BioNTech Booster Gets EUA in 18 and Older
Booster dose is to be administered at least six months after completion of the primary series.11.19.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Gilead Ops in For Three Programs in Arcus Biosciences Portfolio
Aims to accelerate clinical development in oncology and facilitate the exploration of treatment combinations across portfolios.11.18.21
-
Biologics, Proteins, Vaccines | Breaking News | Drug Development | Industry News
Novo Nordisk to Acquire Dicerna Pharmaceuticals for $3.3B
Gains Dicerna’s ribonucleic acid interference (RNAi) platform to develop therapies to selectively silence genes that cause or contribute to disease.11.18.21
-
Breaking News | Facilities
Arxada Invests in Industrial Biotechnological Plant in Kouřim, Czech Republic
Strengthens its capacity to support its expanding customer base.11.18.21
